about
Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questionsMultimodal assessment of microscopic morphology and retinal function in patients with geographic atrophy.Inhibition of cell proliferation, migration and apoptosis in blue-light illuminated human retinal pigment epithelium cells by down-regulation of HtrA1.Quantitative autofluorescence and cell density maps of the human retinal pigment epithelium.Cholecystokinin octapeptide antagonizes apoptosis in human retinal pigment epithelial cellsAge-related macular degeneration: genetics and biology coming together.Histologic basis of variations in retinal pigment epithelium autofluorescence in eyes with geographic atrophy.Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trialRetinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy.Allogenic iPSC-derived RPE cell transplants induce immune response in pigs: a pilot study.Differential DNA methylation identified in the blood and retina of AMD patients.Aflibercept in wet age-related macular degeneration: a perspective reviewTreatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.Subretinal Pigment Epithelial Deposition of Drusen Components Including Hydroxyapatite in a Primary Cell Culture Model.An update on the pharmacotherapy of neovascular age-related macular degeneration.Next-generation therapeutic solutions for age-related macular degeneration.Protective coatings for intraocular wirelessly controlled microrobots for implantation: Corrosion, cell culture, and in vivo animal tests.
P2860
Q26823002-1F07146E-3CE3-4A0D-B1B7-CED726D6AAA2Q30540956-C78C4B02-A83A-4836-AA3E-C0DF31ED436FQ33607722-4C5F17C1-2EE5-4859-9F93-0996A62BEAF7Q34010917-E60A3E9A-E928-4B71-B864-2F4193CF99E9Q34163269-E2553049-5246-4BBF-B20D-D05E30D0985EQ34440797-5B37ACA0-F31B-4DC3-9521-7897CAD94549Q34565798-518DEF81-941B-4A0D-B6B6-C20936534833Q34956193-23D414F0-8CA2-458B-B067-B08AF58D9B9EQ35456717-B624B577-6B70-4385-9219-29979B30451CQ35813401-3433725B-C2AD-42C0-8093-C7C7304E85CDQ36211437-2B990271-3113-484A-892C-85495B3EDA42Q36515577-95E63D9F-161A-489D-8E5B-27A997B0748FQ36801990-F1E6C6B7-B322-4C31-BD97-F92B461E5EA9Q37629530-D821F9AE-F333-40E5-A70B-922416A1CE6DQ38096462-E2F9D63F-067D-47F0-A9A8-F466ABF1A47BQ38138089-82FD93ED-EDEC-4665-AD50-D150A8688079Q50727947-AB042283-97F2-49C0-AFBE-F8A973620C31
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment for atrophic macular degeneration.
@en
Treatment for atrophic macular degeneration.
@nl
type
label
Treatment for atrophic macular degeneration.
@en
Treatment for atrophic macular degeneration.
@nl
prefLabel
Treatment for atrophic macular degeneration.
@en
Treatment for atrophic macular degeneration.
@nl
P1476
Treatment for atrophic macular degeneration.
@en
P2093
Annal D Meleth
P304
P356
10.1097/ICU.0B013E32834594B0
P577
2011-05-01T00:00:00Z